Solid Biosciences News

Boy Given Pfizer Experimental Duchenne Muscular Dystrophy Therapy Dies

Seeking AlphaMay 7 16:16 ET

Solid Biosciences to Present at the American Society of Gene and Cell Therapy Annual Meeting

— Presentations to highlight AAV manufacturing and purification improvements, vector biology updates,and a comprehensive non-clinical data overview of the company's lead SGT-003 program —CHARLESTOWN,

Solid BiosciencesMay 7 00:00 ET

Edgewise Gets EU Orphan Drug Status for Muscular Dystrophy Drug

Seeking AlphaApr 23 10:29 ET

Private Equity Firms Among Solid Biosciences Inc.'s (NASDAQ:SLDB) Largest Stockholders and Were Hit After Last Week's 13% Price Drop

Key Insights Solid Biosciences' significant private equity firms ownership suggests that the key decisions are influenced by shareholders from the larger public A total of 5 investors have a majorit

Simply Wall StApr 11 10:25 ET

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CHARLESTOWN, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, t

Solid BiosciencesApr 3 00:00 ET

Express News | Solid Biosciences Shares Are Trading Higher After the Company Received Rare Pediatric Disease Designation for SGT-003 From the FDA

Moomoo 24/7Apr 2 08:44 ET

Solid Biosciences' SGT-003 Receives US FDA's Rare Pediatric Disease Label

Solid Biosciences (SLDB) said Monday its gene therapy candidate SGT-003 for Duchenne muscular dystrophy has received rare pediatric disease designation from the US Food and Drug Administration. The de

MT NewswiresApr 1 14:04 ET

Solid Biosciences Receives Rare Pediatric Disease Designation From the FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003

– SGT-003 Granted Rare Pediatric Disease, Orphan Drug and Fast Track Designations in U.S. –– Site initiations scheduled for April; patient dosing expected to begin in Q2 2024 –CHARLESTOWN, Mass., Apri

Solid BiosciencesApr 1 00:00 ET

Solid Biosciences Initiated at Outperform by William Blair

Solid Biosciences Initiated at Outperform by William Blair

Dow JonesMar 28 10:52 ET

Express News | William Blair Initiates Coverage On Solid Biosciences With Outperform Rating, Announces Price Target of $40

Moomoo 24/7Mar 28 10:42 ET

Solid Biosciences to Participate at Cantor's Virtual Muscular Dystrophy Symposium

CHARLESTOWN, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, t

Solid BiosciencesMar 27 00:00 ET

Cautious Optimism Amidst Clinical Progress and Regulatory Hurdles for Solid Biosciences

TipRanksMar 19 01:38 ET

Solid Biosciences Is Maintained at Overweight by Barclays

Solid Biosciences Is Maintained at Overweight by Barclays

Dow JonesMar 18 06:35 ET

Express News | Barclays Maintains Overweight on Solid Biosciences, Raises Price Target to $21

Moomoo 24/7Mar 18 06:25 ET

Solid Biosciences (SLDB) Gets a Buy From Barclays

TipRanksMar 18 03:05 ET

Express News | Citigroup Initiates Coverage On Solid Biosciences With Buy Rating, Announces Price Target of $16

Moomoo 24/7Mar 15 10:56 ET

Blend Labs Reports Q4 Results, Joins Alta Equipment, Despegar.com And Other Big Stocks Moving Higher On Friday

U.S. stocks were lower, with the Dow Jones index falling around 100 points on Friday. Shares of Blend Labs, Inc. (NASDAQ:BLND) rose sharply during Friday's session after the company reported fourth-q

BenzingaMar 15 10:25 ET

Analysts Offer Insights on Healthcare Companies: Coherus Biosciences (CHRS) and Solid Biosciences (SLDB)

TipRanksMar 14 20:30 ET

Express News | Solid Biosciences Shares Are Trading Higher After Piper Sandler Upgraded the Stock From Neutral to Overweight and Raised Its Price Target From $8 to $20

Moomoo 24/7Mar 14 08:59 ET

Express News | HC Wainwright & Co. Reiterates Buy on Solid Biosciences, Maintains $16 Price Target

Moomoo 24/7Mar 14 07:30 ET